Literature DB >> 7685168

Reverse transcription-polymerase chain reaction assay demonstrates that the 9-cis retinoic acid receptor alpha is expressed in human osteoblasts.

A Kindmark1, H Törmä, A Johansson, S Ljunghall, H Melhus.   

Abstract

The 9-cis retinoic acid receptor (RXR) alpha, a co-regulator of the thyroid hormone and vitamin D receptors, has previously been shown to be expressed predominantly in metabolic organs such as the liver and the kidney. In this study we have used a reverse transcription polymerase chain reaction (RT-PCR) to examine the expression of retinoic acid (RA) nuclear receptors in primary human osteoblasts and in SaOS-2, a human osteosarcoma-derived cell line with osteoblastic characteristics. Our results demonstrate that human osteoblasts express RXR alpha, as well as the all-trans RA receptors (RAR) alpha, beta, and gamma. These data further establish bone as a major target for retinoids and suggest that RA can regulate vitamin D and thyroid hormone actions in osteoblasts.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7685168     DOI: 10.1006/bbrc.1993.1567

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  3 in total

1.  Inhibitory effects of 9-cis and all-trans retinoic acid on 1,25(OH)2 vitamin D3-induced bone resorption.

Authors:  A Kindmark; H Melhus; S Ljunghall; O Ljunggren
Journal:  Calcif Tissue Int       Date:  1995-09       Impact factor: 4.333

2.  Retinoic acid directly stimulates osteoclastic bone resorption and gene expression of cathepsin K/OC-2.

Authors:  S Saneshige; H Mano; K Tezuka; S Kakudo; Y Mori; Y Honda; A Itabashi; T Yamada; K Miyata; Y Hakeda
Journal:  Biochem J       Date:  1995-08-01       Impact factor: 3.857

3.  Vitamin a is a negative regulator of osteoblast mineralization.

Authors:  Thomas Lind; Anders Sundqvist; Lijuan Hu; Gunnar Pejler; Göran Andersson; Annica Jacobson; Håkan Melhus
Journal:  PLoS One       Date:  2013-12-10       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.